Glioblastoma patients who had downregulated CD73 expression recorded a prolonged median disease-free survival of 7.62 months, whereas patients who had upregulated CD73 had a disease-free survival of 4.73 months (p = 0.0039; z = 2; Figure 2B, left). This evidence concerns the gene NT5E and glioblastoma.